Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F J Giles

Showing results (91-100 of 130) with videos related to

Pageof 13
Sort By:
Leukemia|January 12, 2007
Levels of soluble HLA-I and beta2M in patients with acute myeloid leukemia and advanced myelodysplastic syndrome: association with clinical behavior and outcome of induction therapyM Albitar, M Johnson, K A Do, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 7, 2001
Troxacitabine, a novel dioxolane nucleoside analog, has activity in patients with advanced leukemiaF J Giles, J E Cortes, S D Baker, et al.
Cancer|October 12, 2001
High-dose chemotherapy in high-risk myelodysplastic syndrome: covariate-adjusted comparison of five regimensM Beran, Y Shen, H Kantarjian, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 14, 2000
Homoharringtonine and low-dose cytarabine in the management of late chronic-phase chronic myelogenous leukemiaH M Kantarjian, M Talpaz, T L Smith, et al.
Leukemia & Lymphoma|November 9, 2001
Leukapheresis reduces early mortality in patients with acute myeloid leukemia with high white cell counts but does not improve long- term survivalF J Giles, Y Shen, H M Kantarjian, et al.
Cancer|June 8, 2001
Expression of apoptosis proteins in chronic myelogenous leukemia: associations and significanceF Ravandi, H M Kantarjian, M Talpaz, et al.
Leukemia|November 10, 2012
Phase II study of nilotinib in patients with relapsed or refractory Philadelphia chromosome--positive acute lymphoblastic leukemiaO G Ottmann, R A Larson, H M Kantarjian, et al.
International Journal of Laboratory Hematology|January 15, 2008
Soluble syndecan-1 (sCD138) as a prognostic factor independent of mutation status in patients with chronic lymphocytic leukemiaI Jilani, C Wei, B N Bekele, et al.
Leukemia|November 15, 2011
Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up resultsP D le Coutre, F J Giles, A Hochhaus, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1992
Prospective randomised study of double hemi-body irradiation with and without subsequent maintenance recombinant alpha 2b interferon on survival in patients with relapsed multiple myelomaF J Giles, E N McSweeney, J D Richards, et al.
Pageof 13

Showing results (91-100 of 130) with videos related to

Sort By:
Pageof 13
Leukemia|January 12, 2007
Levels of soluble HLA-I and beta2M in patients with acute myeloid leukemia and advanced myelodysplastic syndrome: association with clinical behavior and outcome of induction therapyM Albitar, M Johnson, K A Do, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 7, 2001
Troxacitabine, a novel dioxolane nucleoside analog, has activity in patients with advanced leukemiaF J Giles, J E Cortes, S D Baker, et al.
Cancer|October 12, 2001
High-dose chemotherapy in high-risk myelodysplastic syndrome: covariate-adjusted comparison of five regimensM Beran, Y Shen, H Kantarjian, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 14, 2000
Homoharringtonine and low-dose cytarabine in the management of late chronic-phase chronic myelogenous leukemiaH M Kantarjian, M Talpaz, T L Smith, et al.
Leukemia & Lymphoma|November 9, 2001
Leukapheresis reduces early mortality in patients with acute myeloid leukemia with high white cell counts but does not improve long- term survivalF J Giles, Y Shen, H M Kantarjian, et al.
Cancer|June 8, 2001
Expression of apoptosis proteins in chronic myelogenous leukemia: associations and significanceF Ravandi, H M Kantarjian, M Talpaz, et al.
Leukemia|November 10, 2012
Phase II study of nilotinib in patients with relapsed or refractory Philadelphia chromosome--positive acute lymphoblastic leukemiaO G Ottmann, R A Larson, H M Kantarjian, et al.
International Journal of Laboratory Hematology|January 15, 2008
Soluble syndecan-1 (sCD138) as a prognostic factor independent of mutation status in patients with chronic lymphocytic leukemiaI Jilani, C Wei, B N Bekele, et al.
Leukemia|November 15, 2011
Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up resultsP D le Coutre, F J Giles, A Hochhaus, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1992
Prospective randomised study of double hemi-body irradiation with and without subsequent maintenance recombinant alpha 2b interferon on survival in patients with relapsed multiple myelomaF J Giles, E N McSweeney, J D Richards, et al.
Pageof 13